AbbVie Doubles Down on Post-Humira Future with Cell Therapy Acquisition and RINVOQ Expansion
AbbVie moves to bolster its pipeline through the acquisition of Capstan Therapeutics for its in vivo CAR-T platform and a regulatory push to expand RINVOQ into vitiligo treatment, signaling a strategic pivot towards complex immunology and oncology.